Literature DB >> 1371820

Biochemical characterization of CD26 (dipeptidyl peptidase IV): functional comparison of distinct epitopes recognized by various anti-CD26 monoclonal antibodies.

Y Torimoto1, N H Dang, T Tanaka, C Prado, S F Schlossman, C Morimoto.   

Abstract

In this paper, we performed further biochemical characterization of the CD26 antigen, as defined by the mAbs in anti-1F7 and anti-Ta1, in order to clarify the observed functional differences among these mAbs. For this purpose, we developed a mAb, anti-5F8, which recognizes yet another epitope on the CD26 antigen different from that recognized by anti-1F7 and anti-Ta1 and compared their respective effect on T cell activation as well as the structures recognized by these mAbs. Functionally, anti-5F8 did not exhibit a comitogenic effect on T cell activation via the CD3 and CD2 pathways. Peptide mapping studies suggested that the 110 kDa molecules precipitated by these mAbs are identical. We showed that the 110 kDa CD26 structure on human T cells is composed of a family of heterogeneous molecules, as determined by isoelectric focusing studies. In addition, we demonstrated that the CD26 antigen has a DPPIV enzyme activity and this enzyme activity is found only on the principal basic structure of CD26 but not on the additional acidic structures. Biochemical studies also revealed that these mAbs recognized distinct epitopes on the CD26 antigen. Pulse-chase studies showed the the 1F7 epitope was found on both the immature (100 kDa) and mature (110 kDa) forms of the CD26 antigen. On the other hand, the Ta1 and 5F8 epitopes were expressed mainly on the mature form of the CD26 antigen. Moreover, anti-IF7 consistently precipitated an additional 43 kDa molecule in association with the principal 110 kDa molecule. Taken together, these data suggested that the additional 43 kDa structure or the distinct epitope recognized by anti-IF7 may play a role in human T cell activation via the CD3 and CD2 pathways.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1371820     DOI: 10.1016/0161-5890(92)90099-j

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  14 in total

1.  Comparison of two commercial ELISAs against an in-house ELISA for measuring soluble CD26 in human serum.

Authors:  Kei Ohnuma; Tatsuhiko Saito; Ryou Hatano; Osamu Hosono; Satoshi Iwata; Nam H Dang; Hiroki Ninomiya; Chikao Morimoto
Journal:  J Clin Lab Anal       Date:  2014-03-28       Impact factor: 2.352

2.  CD26-mediated co-stimulation in human CD8(+) T cells provokes effector function via pro-inflammatory cytokine production.

Authors:  Ryo Hatano; Kei Ohnuma; Junpei Yamamoto; Nam H Dang; Chikao Morimoto
Journal:  Immunology       Date:  2013-02       Impact factor: 7.397

3.  Internalization of CD26 by mannose 6-phosphate/insulin-like growth factor II receptor contributes to T cell activation.

Authors:  H Ikushima; Y Munakata; T Ishii; S Iwata; M Terashima; H Tanaka; S F Schlossman; C Morimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

4.  G1/S cell cycle arrest provoked in human T cells by antibody to CD26.

Authors:  Kei Ohnuma; Tomonori Ishii; Satoshi Iwata; Osamu Hosono; Hiroshi Kawasaki; Masahiko Uchiyama; Hirotoshi Tanaka; Tadanori Yamochi; Nam H Dang; Chikao Morimoto
Journal:  Immunology       Date:  2002-11       Impact factor: 7.397

5.  Regulation of epithelial and lymphocyte cell adhesion by adenosine deaminase-CD26 interaction.

Authors:  Silvia Ginés; Marta Mariño; Josefa Mallol; Enric I Canela; Chikao Morimoto; Christian Callebaut; Ara Hovanessian; Vicent Casadó; Carmen Lluis; Rafael Franco
Journal:  Biochem J       Date:  2002-01-15       Impact factor: 3.857

6.  The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity.

Authors:  T Tanaka; J Kameoka; A Yaron; S F Schlossman; C Morimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

7.  Role of CD26/dipeptidyl peptidase IV in human immunodeficiency virus type 1 infection and apoptosis.

Authors:  C Morimoto; C I Lord; C Zhang; J S Duke-Cohan; N L Letvin; S F Schlossman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

8.  Enhancement of antigen-induced T-cell proliferation by soluble CD26/dipeptidyl peptidase IV.

Authors:  T Tanaka; J S Duke-Cohan; J Kameoka; A Yaron; I Lee; S F Schlossman; C Morimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

9.  First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers.

Authors:  Eric Angevin; Nicolas Isambert; Véronique Trillet-Lenoir; Benoit You; Jérôme Alexandre; Gérard Zalcman; Philippe Vielh; Françoise Farace; Fanny Valleix; Thomas Podoll; Yu Kuramochi; Itaru Miyashita; Osamu Hosono; Nam H Dang; Kei Ohnuma; Taketo Yamada; Yutaro Kaneko; Chikao Morimoto
Journal:  Br J Cancer       Date:  2017-03-14       Impact factor: 7.640

10.  CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myeloma.

Authors:  Hiroko Nishida; Mutsumi Hayashi; Chikao Morimoto; Michiie Sakamoto; Taketo Yamada
Journal:  Blood Cancer J       Date:  2018-10-22       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.